|

TAS-102, oxaliplatin, irinotecan with bevacizumab Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 2: 1

Top Sponsors

  • Rutgers, The State University of New Jersey1

Indications

  • Rectal Cancer1
  • Colon Cancer1
  • Cancer1

Elizabeth, New Jersey1 trial

Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer

Trinitas Hospital and Comprehensive Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.